The Latest Cardiac and Vascular News
–The STORM-PE RCT data presented at the VIVA 2025 Conference showed PE patients treated with CAVT in combination with anticoagulation demonstrated significantly greater improvements in thrombus burden reduction, heart rate, oxygen requirement, and functional outcomes compared to those who received only anticoagulation –Results of STORM-PE demonstrating superior efficacy of […]
ALAMEDA, Calif. – Oct. 27, 2025 – Penumbra, Inc. (NYSE: PEN) announced the results of the landmark STORM-PE randomized controlled trial (RCT), which found that the use of mechanical thrombectomy, specifically computer assisted vacuum thrombectomy (CAVT™), with anticoagulation achieved superior reduction in right heart strain compared to anticoagulation therapy alone in […]
ALAMEDA, Calif., Oct. 8, 2025 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN) today announced that it will host an investor event on Sunday, October 26, 2025 from 4:00-5:00 PM Pacific Time / 7:00-8:00 PM Eastern Time at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) Conference….
Penumbra recently announced that Lightning Bolt® 6X with TraX,™ designed to reach and confidently remove thrombus below the knee, is now available in a 150 cm catheter length. This longer option brings the power and efficiency of Penumbra’s Computer Assisted Vacuum Thrombectomy (CAVT™) to the distal arteries in the body. “Lightning Bolt […]
Penumbra Inc., the world’s leading thrombectomy company, has secured CE Mark for its SwiftPAC™ neuro embolisation coil, which is part of the Swift™ Coil System and is now commercially available in Europe. Penumbra’s SwiftPAC coils are designed as a soft space-seeking “liquid metal” that conforms to the target vessel for dense […]
ALAMEDA, Calif., June 5, 2025 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN) announced the U.S. Food and Drug Administration (FDA) clearance and launch of the Ruby® XL System, the longest, largest and softest coil on the marketi. The Ruby XL System is designed to help physicians achieve more…
ALAMEDA, Calif., April 2, 2025 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, announced seven significant computer assisted vacuum thrombectomy (CAVT™) data presentations during the 2025 Society of Interventional Radiology (SIR) Annual Scientific…
Data presented for the first time this week at Vascular Interventional Advances (VIVA) 2024 Conference Findings reinforce the clinical, health economic and cost benefits of computer assisted vacuum thrombectomy to patients and the overall health system ALAMEDA, Calif., Nov. 5, 2024…
ALAMEDA, Calif., Oct. 14, 2024 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, announced the completion of enrollment in its THUNDER clinical study for patients with acute ischemic stroke. THUNDER is evaluating the safety and efficacy of the company’s…
Campaign is led by prominent medical societies to minimize discrepancies in treating blood clot conditions, such as in pulmonary embolism, where there are often delays in care (up to 26% of patients in one study) and misdiagnosis (up to 53% of patients in one study)1,2 ALAMEDA, Calif.,…
